JabWell — your AI nurse and coach for every GLP-1 shot

JabWell is an educational companion app for adults using GLP-1 medications. It combines smart injection tracking with four coaching layers most trackers do not include: a 24/7 AI nurse chat that cites FDA, AAFP, Mayo Clinic, and Cleveland Clinic on every answer; a protein coach calibrated for GLP-1 appetite suppression; a plateau detector that generates specific prescriber questions; and a weekly hair-and-skin photo journal. It auto-generates a 12-week PDF summary for doctor visits. It does not prescribe, diagnose, or recommend dose changes.

No. JabWell is an educational companion app. It is not a medical device. It does not prescribe medication, does not recommend dose changes, and does not diagnose conditions. Every AI reply cites its public source and tells you when to consult your prescriber. For severe symptoms — vomiting more than 24 hours, severe abdominal pain that radiates to the back, signs of allergic reaction, severe dehydration — stop using the app and seek emergency care. In the US call 911 or Poison Control at 1-800-222-1222.

Ozempic, Wegovy, and Rybelsus (semaglutide, Novo Nordisk); Mounjaro and Zepbound (tirzepatide, Eli Lilly); Saxenda and Victoza (liraglutide, Novo Nordisk); Trulicity (dulaglutide, Eli Lilly); plus compounded semaglutide and tirzepatide from authorized 503A and 503B pharmacies. Each medication has its own titration schedule and medication-level curve in the app.

FDA prescribing information for each GLP-1 medication, AAFP (American Academy of Family Physicians) clinical guidelines, Mayo Clinic and Cleveland Clinic patient-facing educational content, and peer-reviewed studies on semaglutide, tirzepatide, liraglutide, and dulaglutide. Every reply cites its source. The AI nurse is not a registered nurse, not a healthcare provider, and not your prescriber.

No. It is a language model prompted in the style of a nurse-educator, grounded in publicly available sources. It cannot diagnose or prescribe. It can explain what FDA prescribing information says about your medication, what AAFP recommends for common side effects, and what your three-tier triage looks like — common / worth flagging / stop and call prescriber.

Shotsy is an excellent pure GLP-1 tracker: dose log, site rotation, medication-level estimates, Apple Health sync, doctor-visit PDF. JabWell does the same and adds four coaching layers on top: AI nurse chat with source citations, protein coach calibrated for GLP-1, plateau detector that generates prescriber questions, and weekly hair-and-skin photo journal. Pure tracking → Shotsy. Tracking plus coaching → JabWell.

No. JabWell will tell you that you have hit a four-plus-week plateau and will generate the questions to bring to your prescriber. It will not recommend a specific dose change. Dose decisions belong to the person prescribing the medication.

Per FDA prescribing information for semaglutide and tirzepatide, nausea is most common in the first weeks after each dose increase and tends to decrease over time. Most people report that nausea subsides within 1–4 weeks of a given dose. If nausea persists beyond 4 weeks at a stable dose, or includes vomiting more than 24 hours, that is the threshold to call your prescriber. JabWell does not diagnose — this is informational only.

Sulfur burps are belches that smell like rotten eggs. They are a commonly-reported side effect of semaglutide and tirzepatide, linked to delayed gastric emptying that the medications cause. Dietary adjustments (smaller meals, less high-fat or high-sulfur food) and adequate hydration often help. Persistent sulfur burps lasting more than 2 weeks, especially with abdominal pain, are worth flagging to your prescriber.

Hair shedding is a reported but not formally listed side effect of GLP-1 receptor agonists. Most clinicians attribute it to rapid weight loss (telogen effluvium) rather than a direct effect of the medication. It typically resolves once weight loss stabilizes. JabWell's weekly hair-and-skin photo journal lets you track changes against your actual weight trend. If shedding is significant, your prescriber may suggest checking ferritin, vitamin D, and protein intake.

The plateau detector looks at your last 30 days of weight data and flags if your weight has stayed within a ±0.5 kg / ±1 lb band for four or more consecutive weeks. When triggered, it generates a structured set of questions to bring to your prescriber: dose history, protein adherence, steps, sleep, and specific titration-timing questions sourced from FDA prescribing information for your medication. JabWell does not recommend a dose change — that is your prescriber's decision.

Yes. Compounded semaglutide pharmacokinetics are the same active molecule as Ozempic and Wegovy. The medication-level curve in JabWell is based on peer-reviewed semaglutide half-life data and applies regardless of whether the source is brand or compounded.

Yes. JabWell supports compounded semaglutide and tirzepatide from authorized 503A and 503B pharmacies. The medication-level curves use the same pharmacokinetic data as the brand medications, since the active molecule is identical. Compounded users have access to all features — AI nurse, protein coach, plateau detector. Note: the FDA has issued statements about compounded GLP-1 supply changes; consult your pharmacy and prescriber on current availability and quality.

JabWell supports tracking multiple medications simultaneously, so a switch mid-course is supported. You can mark the end date of the previous medication and start logging the new one. Your weight trend, side-effect history, and doctor-visit PDF continue across the switch. The medication-level chart updates to reflect the new active ingredient curve (tirzepatide instead of semaglutide).

Supported. Trulicity (dulaglutide) is weekly. Saxenda (liraglutide) is daily. JabWell handles both schedules and adjusts the medication-level curve for each active ingredient.

Per FDA prescribing information for each medication, missed-dose guidance varies. For Ozempic and Wegovy (semaglutide weekly), if it has been less than 5 days, take the missed dose; if more than 5 days, skip it and take the next dose on your normal day. For Mounjaro and Zepbound (tirzepatide weekly), if it has been less than 4 days, take it; otherwise skip. JabWell's AI nurse can pull the specific FDA missed-dose protocol for your medication — but if you are unsure, contact your prescribing provider or pharmacy.

Tracking, reminders, journal photos, and the doctor-visit PDF all work offline. The AI nurse chat needs internet for the language model call. The protein coach and plateau detector run on-device once your data is logged.

No. JabWell is privacy-first: your data stays on your device by default. No account is required to use the core tracker. AI nurse chat messages are routed through a privacy proxy and are not linked to your identity. JabWell does not sell, share, or monetize health data. The only exception is the affiliate disclosure — we may earn a commission when you choose to sign up with a compounded pharmacy partner through an in-app link, and that link is clearly labeled.

JabWell Premium is $4.99 per week or $39.99 per year, with a 7-day free trial on both plans. The annual subscription works out to about $0.77 per week — an 85% discount versus the weekly plan. Subscriptions auto-renew unless cancelled at least 24 hours before the period ends. Manage or cancel in iPhone Settings → Apple ID → Subscriptions.

Yes. JabWell supports Apple Family Sharing on subscription plans, so a couple managing two GLP-1 prescriptions on one family plan only pays one subscription. Each Family Sharing member uses their own iPhone with their own private data — there is no shared journal.

You keep your local data on your device. You lose access to AI nurse chat, plateau detector AI analysis, and hair-journal AI flagging. You keep manual logging and the doctor-visit PDF feature.

JabWell is designed for adults using GLP-1 medications. Both type 2 diabetes management (the original FDA indication for Ozempic) and weight management are common reasons for prescription. The injection tracker, AI nurse, protein coach, and doctor-visit PDF are useful for either case. JabWell is not a diabetes management app — it does not track blood glucose, A1C, or carbohydrate ratios. For diabetes management combine JabWell with a CGM app or your endocrinologist's preferred tool.

Yes. The doctor-visit PDF exports a 12-week summary as a PDF you can email, AirDrop, or attach to a patient portal message. Weight data can also be exported to Apple Health. Photos in the hair-and-skin journal can be exported individually. Full database CSV export is on the roadmap.

HIPAA applies to covered entities (healthcare providers, health plans, clearinghouses) and their business associates. JabWell is a direct-to-consumer iOS app and is not a covered entity, so HIPAA does not apply the same way it applies to your doctor's EHR. Practically, we go beyond HIPAA-style protections: no account required for the core tracker, local-first data storage by default, AI nurse messages routed through a privacy proxy with no user identifier, no health-data sale or advertising. iCloud sync is opt-in and uses Apple's encrypted iCloud.

Stop using the app and seek immediate care for: vomiting that lasts more than 24 hours; severe abdominal pain (especially radiating to the back — possible pancreatitis); signs of allergic reaction such as facial swelling, hives, or difficulty breathing; severe dehydration; vision changes (for diabetes users — possible retinopathy progression); severe depression or suicidal thoughts. In the US call 911 or Poison Control at 1-800-222-1222. JabWell is not equipped to handle emergencies and the AI nurse will redirect you to emergency care when these triggers appear.